HDAC9 and amyotrophic lateral sclerosis: We hypothesize that the toxic side effects are due to the non-specificity of the HDAC inhibitors that may change the acetylation status of yet undefined substrates of deacetylases and/or products of acetylases, particularly in the insoluble protein aggregates relevant to the pathogenesis of ALS.